Dr. Frank Borriello will deliver an oral presentation at the Immuno-Oncology Summit 2022 in Boston, MA
Dr. Borriello’s presentation on the topic of ‘Therapeutic SUPLEXA Cells – A Clinical Stage, Non-Engineered, Tumor Agnostic Cellular Therapy ‘ will be held at 3.05 pm on Day 2 (Friday 14 October) of the the Immuno-Oncology Summit 2022 (Seaport Hotel, Boston, MA).
If you are planning to attend the Summit; please come along and introduce yourself.
Further details on the summit are available from: https://www.immuno-oncologysummit.com/T-Cell#
SUPLEXA therapeutic cells are comprised of activated autologous NK, NKT and T cells of both the gamma-delta and alpha-beta varieties, which are capable of recognizing and killing a broad range of tumor cells. They are manufactured in a robust and cost effective 2-week process beginning with patient-derived PBMC isolated from 50 mL of peripheral blood. The key step in the manufacturing process involves a coincubation of the PBMC with proprietary engineered tumor cells that express a variety of immunomodulatory ligands. A first-in-human clinical basket study is underway in Australia that includes patients with solid tumors and hematologic malignancies.